Fred Hutch Researchers Develop Breakthrough Human Monoclonal Antibodies to Block Epstein-Barr Virus Infection

Fred Hutch researchers use humanized mice to create antibodies that stop EBV infection. Learn how this could prevent cancer and save transplant patients.

By: AXL Media

Published: Apr 15, 2026, 10:20 AM EDT

Source: Information for this report was sourced from Fred Hutchinson Cancer Center

A Major Advance Against a Global Pathogen

Researchers at Fred Hutch Cancer Center have achieved a critical milestone in the fight against the Epstein-Barr virus, a pathogen that resides in approximately 95% of the global population. While often dormant, the virus is a known trigger for various cancers, neurodegenerative diseases, and chronic illnesses. By utilizing mice engineered with human antibody genes, the research team developed monoclonal antibodies capable of neutralizing the virus before it can infiltrate human B cells. This breakthrough provides a potential roadmap for the first effective clinical defense against a virus that has historically evaded pharmaceutical intervention.

Targeting the Viral Entry Mechanism

The success of this study rests on the strategic targeting of two specific viral proteins, known as gp350 and gp42. The gp350 protein is responsible for the initial attachment of the virus to human cells, while gp42 facilitates the fusion and entry process. According to Andrew McGuire, PhD, a biochemist at Fred Hutch, finding antibodies that block this process without being rejected by the human immune system has been a multi-year challenge. By identifying two antibodies for gp350 and eight for gp42, the team has successfully mapped the virus's structural vulnerabilities, allowing for the creation of therapies that mimic natural human defenses.

Clinical Solutions for High Risk Transplant Patients

The most immediate application of this discovery lies in the field of transplant medicine, where over 128,000 Americans undergo procedures annually. These patients must take immunosuppressive drugs to prevent organ rejection, which inadvertently allows latent Epstein-Barr virus to reactivate or spread through donor tissue. This uncontrolled viral activity often leads to post-transplant lymphoproliferative disorders, a dangerous form of lymphoma. Dr. Rachel Bender Ignacio, an infectious disease physician, emphasized that preventing this viral spread is a significant unmet need that could preserve organ function and save lives.